Sandbox:Roukoz: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 22: | Line 22: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Unique features | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Unique features | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous squamous cell carcinoma''' | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''SCC in situ (Bowen's disease''') | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Usually asymptomatic | * Usually asymptomatic | ||
Line 69: | Line 69: | ||
| style="background: #F5F5F5; padding: 5px;" |same as above | | style="background: #F5F5F5; padding: 5px;" |same as above | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma''' | ||
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic | | style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 103: | Line 103: | ||
* It is controversial whether keratoacanthomas represent a subtype of well-differentiated SCC or a separate entity | * It is controversial whether keratoacanthomas represent a subtype of well-differentiated SCC or a separate entity | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Merkel cell carcinoma''' | ||
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic | | style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 121: | Line 121: | ||
| style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule | | style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Nodular basal cell carcinoma''' | ||
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic | | style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 134: | Line 134: | ||
| style="background: #F5F5F5; padding: 5px;" |Ulceration is frequent, and the term "rodent ulcer" refers to these ulcerated nodular BCCs | | style="background: #F5F5F5; padding: 5px;" |Ulceration is frequent, and the term "rodent ulcer" refers to these ulcerated nodular BCCs | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Superficial basal cell carcinoma ''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 149: | Line 149: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Prurigo nodules''' | ||
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic | | style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 172: | Line 172: | ||
upper midback area is usually spared | upper midback area is usually spared | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Common nevus''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 190: | Line 190: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Blue nevus''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 209: | Line 209: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Spitz nevus''' | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;"|Nonpigmented Spitz nevus | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Nonpigmented Spitz nevus''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 223: | Line 223: | ||
| style="background: #F5F5F5; padding: 5px;" |benign, indolent melanocyte proliferation that most commonly develops in children, adolescents, and young adults. | | style="background: #F5F5F5; padding: 5px;" |benign, indolent melanocyte proliferation that most commonly develops in children, adolescents, and young adults. | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;"|Reed-like Spitz | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Reed-like Spitz''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 237: | Line 237: | ||
| style="background: #F5F5F5; padding: 5px;" |benign, indolent melanocyte proliferation that most commonly develops in children, adolescents, and young adults. | | style="background: #F5F5F5; padding: 5px;" |benign, indolent melanocyte proliferation that most commonly develops in children, adolescents, and young adults. | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Solar lentigo''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 250: | Line 250: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Lentigo Maligna''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 263: | Line 263: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Lentigo Maligna Melanoma''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 276: | Line 276: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Sebaceous hyperplasia''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 289: | Line 289: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Lichen planus-like keratosis''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 302: | Line 302: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Seborrheic keratosis''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 315: | Line 315: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Actinic keratosis''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 328: | Line 328: | ||
| style="background: #F5F5F5; padding: 5px;" |painful | | style="background: #F5F5F5; padding: 5px;" |painful | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Nodular malignant melanoma''' | ||
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic | | style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 343: | Line 343: | ||
* Genetic component in some cases with a positive family history | * Genetic component in some cases with a positive family history | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center; | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Amelanotic melanoma''' | ||
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic | | style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 00:27, 19 February 2019
Diseases | Clinical manifestations | Para-clinical findings | Additional findings | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Skin Examination | |||||||||||
Lab Findings | Histopathology | |||||||||||
Symptoms | Symptoms | Dermoscopic Findings | Skin exam 1 | Skin exam 2 | Skin exam 3 | Risk factors | Areas affected | Unique features | ||||
Cutaneous squamous cell carcinoma | SCC in situ (Bowen's disease) |
|
|
|
|
|
|
|
|
| ||
Invasive squamous cell carcinoma |
|
|
|
|
|
|
|
same as above | same as above | same as above | ||
Keratoacanthoma | Usually asymptomatic | White circles, keratin, blood spots, and white structureless zones | Initial lesion: small pink macule
Later: papular quality and eventually forms a circumscribed nodule. |
The periphery of the nodule tends to be skin-colored or mildly erythematous and may have accompanying telangiectasias | The center of the nodule typically demonstrates a prominent keratinous core. |
|
|
a history of rapid growth within weeks favors this diagnosis |
|
| ||
Merkel cell carcinoma | Usually asymptomatic | Milky red areas; linear, irregular vessels; and polymorphous vessels | rapidly growing, painless, firm, nontender, shiny, flesh-colored or bluish-red, intracutaneous nodule | No more additional findings | No more additional findings | Older patients with light skin tones |
|
|
Blue-red, dome-shaped nodule | |||
Nodular basal cell carcinoma | Usually asymptomatic | Pearly papule with telangiectasias | Pink or flesh-colored papule | No more additional findings | none | Typically presents on the face | May have a "rolled" border, where the periphery is more raised than the middle. | Ulceration is frequent, and the term "rodent ulcer" refers to these ulcerated nodular BCCs | ||||
Superficial basal cell carcinoma | Scaly patch | Erythematous lesion | No more additional findings |
|
||||||||
Prurigo nodules | Usually asymptomatic | Firm, dome-shaped and itchy | ranging in size from a few millimeters to several centimeters and often symmetrically distributed | Nodules can be flesh-colored, erythematous, or brown/black | none |
|
Worsened by heat, sweating, or irritation from clothing |
|
Nodules range in number from few to hundreds
upper midback area is usually spared | |||
Common nevus |
|
|
|
|||||||||
Blue nevus |
|
|
|
|||||||||
Spitz nevus | Nonpigmented Spitz nevus | coiled vessels and a white network (also called reticular depigmentation or negative network) over a pink to reddish background | benign, indolent melanocyte proliferation that most commonly develops in children, adolescents, and young adults. | |||||||||
Reed-like Spitz | coiled vessels and a white network (also called reticular depigmentation or negative network) over a pink to reddish background | benign, indolent melanocyte proliferation that most commonly develops in children, adolescents, and young adults. | ||||||||||
Solar lentigo | ||||||||||||
Lentigo Maligna | ||||||||||||
Lentigo Maligna Melanoma | ||||||||||||
Sebaceous hyperplasia | ||||||||||||
Lichen planus-like keratosis | ||||||||||||
Seborrheic keratosis | ||||||||||||
Actinic keratosis | less pigmentation, and tend to be somewhat smaller in size. | Erythema | Hyperkeratosis | painful | ||||||||
Nodular malignant melanoma | Usually asymptomatic | Lump that has been rapidly growing over the past weeks | No more additional findings | No more additional findings | none | Cells proliferate downwards through the skin (vertical growth) |
| |||||
Amelanotic melanoma | Usually asymptomatic | Color usually pink, purple or normal skin color | Usually have an asymmetrical shape with an irregular border | Red, nonspecific lesion with slightly elevated borders |
|
SCC in situ: Frequently, there is associated thickening of the epidermis (acanthosis), as well as hyperkeratosis and parakeratosis of the stratum corneum. In contrast to SCC in situ, actinic keratoses demonstrate only partial-thickness epidermal dysplasia.